Venture Certified
| 기술평가보증기업(기금) | 2018-05-11 ~ 2020-05-10 | 20180105608 | 2018-05-11 |
| 기술평가보증기업(기금) | 2020-05-11 ~ 2022-05-10 | 20200107589 | 2018-05-11 |
| 연구개발유형 | 2022-05-11 ~ 2025-05-10 | 20220421020004 | 2018-05-11 |
| 연구개발유형 | 2025-05-11 ~ 2028-05-10 | 20250409020023 | 2018-05-11 |
Revenue CAGR +65.2%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 1.5B | 0.4B | 0.6B |
| Operating Profit | -1.6B | -2.6B | -3.2B |
| Net Profit | -0.0B | -1.0B | -2.2B |
| Total Assets | 1.6B | 1.5B | 1.5B |
| Total Liabilities | 2.3B | 2.2B | 1.2B |
| Total Equity | -0.7B | -0.7B | 0.3B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -2B
3 Consecutive Years of Net Loss
▲ 231.5%
▲ 45.1%
▲ 83.8%
▼ 804.7%
▲ 100.3%
| Name | Position | Role |
|---|---|---|
| 이원재 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 관악구",
"ceo_name": "이원재",
"certificate": [
{
"cert_number": "20180105608",
"changes": "",
"disclosure_date": "2018-05-11",
"first_cert_date": "2018-05-11",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2018-05-11 ~ 2020-05-10"
},
{
"cert_number": "20200107589",
"changes": "",
"disclosure_date": "2020-06-08",
"first_cert_date": "2018-05-11",
"no": "2",
"type": "기술평가보증기업(기금)",
"valid_period": "2020-05-11 ~ 2022-05-10"
},
{
"cert_number": "20220421020004",
"changes": "",
"disclosure_date": "2022-04-21",
"first_cert_date": "2018-05-11",
"no": "3",
"type": "연구개발유형",
"valid_period": "2022-05-11 ~ 2025-05-10"
},
{
"cert_number": "20250409020023",
"changes": "",
"disclosure_date": "2025-04-09",
"first_cert_date": "2018-05-11",
"no": "4",
"type": "연구개발유형",
"valid_period": "2025-05-11 ~ 2028-05-10"
}
],
"company_name": "(주)새로운바이오(SAELOUN BIO CO.,Ltd)",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 60000000,
"cost_of_sales": 0,
"current_assets": 77234000,
"current_liabilities": 117240000,
"gross_profit": 56160000,
"net_income": -224954000,
"net_income_bs": -224954000,
"non_current_assets": 68798000,
"non_current_liabilities": 0,
"non_operating_expenses": 2897000,
"non_operating_income": 101798000,
"operating_profit": -323855000,
"revenue": 56160000,
"sga_expenses": 380015000,
"total_assets": 146032000,
"total_equity": 28792000,
"total_liabilities": 117240000
},
"2023": {
"capital_stock": 60000000,
"cost_of_sales": 0,
"current_assets": 78016000,
"current_liabilities": 216018000,
"gross_profit": 36364000,
"net_income": -97997000,
"net_income_bs": -97997000,
"non_current_assets": 68798000,
"non_current_liabilities": 0,
"non_operating_expenses": 10922000,
"non_operating_income": 169966000,
"operating_profit": -257041000,
"revenue": 36364000,
"sga_expenses": 293405000,
"total_assets": 146814000,
"total_equity": -69204000,
"total_liabilities": 216018000
},
"2024": {
"capital_stock": 60000000,
"cost_of_sales": 0,
"current_assets": 95156000,
"current_liabilities": 233745000,
"gross_profit": 153349000,
"net_income": -587000,
"net_income_bs": -587000,
"non_current_assets": 68798000,
"non_current_liabilities": 0,
"non_operating_expenses": 11407000,
"non_operating_income": 170254000,
"operating_profit": -159434000,
"revenue": 153349000,
"sga_expenses": 312783000,
"total_assets": 163954000,
"total_equity": -69791000,
"total_liabilities": 233745000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "환경병증 치료제 개발, For-baby",
"phone": "02-880-****",
"years": [
2024,
2023,
2022
]
}